UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Homologous recombination deficiency in triple negative breast cancer

Breast (Edinburgh), 2019-06, Vol.45, p.15-21

2019

Volltextzugriff (PDF)

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Cancers, 2022-09, Vol.14 (17), p.4278

2022

Volltextzugriff (PDF)

Liver toxicity in the era of immune checkpoint inhibitors: A practical approach

Critical reviews in oncology/hematology, 2018-12, Vol.132, p.125-129

2018

Volltextzugriff (PDF)

Adjuvant treatment in biliary tract cancer： To treat or not to treat

World journal of gastroenterology : WJG, 2012-06, Vol.18 (21), p.2591-2596

2012

Volltextzugriff (PDF)

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting

Cancers, 2024-01, Vol.16 (2), p.281

2024

Volltextzugriff (PDF)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

Cancers, 2021-11, Vol.13 (22), p.5829

2021

Volltextzugriff (PDF)

Role of taxanes in pancreatic cancer

World journal of gastroenterology : WJG, 2012-09, Vol.18 (33), p.4457-4465

2012

Volltextzugriff (PDF)

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

Cancer chemotherapy and pharmacology, 2012-01, Vol.69 (1), p.115-123

2012

Volltextzugriff (PDF)

530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A603-A604

2023

Volltextzugriff (PDF)

Targeting the microenvironment in solid tumors

Cancer treatment reviews, 2018-04, Vol.65, p.22-32

2018

Volltextzugriff (PDF)

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A503-A503

2021

Volltextzugriff (PDF)

The emerging role of PI3K inhibitors for solid tumour treatment and beyond

British journal of cancer, 2023-06, Vol.128 (12), p.2150-2162

2023

Volltextzugriff (PDF)

The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review

European journal of cancer (1990), 2019-08, Vol.117, p.14-31

2019

Volltextzugriff (PDF)

Progresses Toward Precision Medicine in RET -altered Solid Tumors

Clinical cancer research, 2020-12, Vol.26 (23), p.6102-6111

2020

Volltextzugriff (PDF)

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Journal of Oncology, 2009-01, Vol.2009 (2009), p.1-8

2009

Volltextzugriff (PDF)

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

Investigational new drugs, 2022-10, Vol.40 (5), p.1133-1136

2022

Volltextzugriff (PDF)

(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial

Clinical cancer research, 2016-03, Vol.22 (5), p.1076-1085

2016

Volltextzugriff (PDF)

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity

European journal of cancer (1990), 2020-12, Vol.141, p.218-224

2020

Volltextzugriff (PDF)

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

Cancer, 2016-02, Vol.122 (4), p.574-581

2016

Volltextzugriff (PDF)

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

European journal of cancer (1990), 2021-06, Vol.150, p.155-167

2021

Volltextzugriff (PDF)

Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents

European journal of cancer (1990), 2020-11, Vol.139, p.92-98

2020

Volltextzugriff (PDF)

A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data

European journal of cancer (1990), 2023-09, Vol.190, p.112958-112958, Article 112958

2023

Volltextzugriff (PDF)

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Cancer treatment reviews, 2024-07, Vol.128, p.102761-102761, Article 102761

2024

Volltextzugriff (PDF)

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions

Expert review of clinical pharmacology, 2021-10, Vol.14 (10), p.1233-1252

2021

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(101)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Homologous recombination deficiency in triple negative breast cancer

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Liver toxicity in the era of immune checkpoint inhibitors: A practical approach

Adjuvant treatment in biliary tract cancer： To treat or not to treat

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

Role of taxanes in pancreatic cancer

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Targeting the microenvironment in solid tumors

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

The emerging role of PI3K inhibitors for solid tumour treatment and beyond

The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review

Progresses Toward Precision Medicine in RET -altered Solid Tumors

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046

(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity

Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti‐BIL study)

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents

A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions

Suchergebnisse filtern